What’s Happening

Merck and Japan-based pharmaceutical company Daiichi Sankyo have withdrawn their U.S. application seeking accelerated approval for an experimental lung cancer treatment called ifinatamab deruxtecan.

The decision came after discussions with the U.S. Food and Drug Administration. The FDA determined that data from a mid-stage clinical trial did not meet the requirements needed to support accelerated approval.

The drug was being developed for adults with extensive-stage small cell lung cancer, an aggressive form of lung cancer, whose disease had worsened after standard chemotherapy. (Reuters)

What Is Ifinatamab Deruxtecan?

Ifinatamab deruxtecan is an antibody-drug conjugate, or ADC.

ADC medicines are designed to deliver a cancer-killing drug directly toward tumor cells. They combine an antibody that recognizes a specific target with a powerful drug payload.

In this case, ifinatamab deruxtecan targets a protein called B7-H3, which is found at high levels in several types of cancer.

The goal is to use the antibody as a kind of targeting system to deliver the drug payload to cancer cells while limiting exposure to healthy tissue.

Why Was Accelerated Approval Sought?

The companies had asked the FDA to approve the drug through the accelerated approval pathway.

This pathway can allow certain medicines for serious conditions to reach patients sooner when early clinical evidence suggests they may provide meaningful benefits.

However, accelerated approval requires the submitted evidence to meet specific regulatory standards.

After reviewing the available data, the FDA determined that the results from the mid-stage study were not sufficient to support an early approval.

As a result, Merck and Daiichi Sankyo withdrew the application. (Reuters)

What Happened to the Clinical Program?

The withdrawal does not mean development of ifinatamab deruxtecan has ended.

The companies are continuing to study the drug in Phase 3 clinical trials.

One ongoing study is evaluating the treatment in patients with extensive-stage small cell lung cancer. Additional studies are evaluating the drug in other difficult-to-treat cancers.

This means the companies can continue collecting data to better understand the drug's potential and whether a future application could be supported by stronger evidence. (MarketScreener)

What’s Changing / Business Impact

The withdrawal is another setback for Merck and Daiichi Sankyo's large cancer partnership.

The companies entered into a collaboration in 2023 worth up to $22 billion to jointly develop and commercialize three antibody-drug conjugates.

Ifinatamab deruxtecan is one of those three programs.

Another drug from the partnership, patritumab deruxtecan, also faced a U.S. application withdrawal. That drug was being investigated for a type of non-small cell lung cancer and was withdrawn after a late-stage study failed to show an improvement in overall survival.

The third program, raludotatug deruxtecan, remains part of the collaboration's development pipeline. (Reuters)

The developments show the risks involved in large pharmaceutical partnerships: even when companies commit billions to a group of promising therapies, individual programs can still encounter clinical or regulatory setbacks.

Why This Matters

Small cell lung cancer is an aggressive disease with limited treatment options, particularly after the disease returns or continues progressing following chemotherapy.

The withdrawal means ifinatamab deruxtecan will not receive accelerated U.S. approval based on the current application.

However, the ongoing Phase 3 program means there is still an opportunity for the treatment to generate additional evidence.

For Merck and Daiichi Sankyo, the results will also be important for determining how the companies allocate resources across their broader oncology pipeline.

Looking Ahead

The companies will continue evaluating ifinatamab deruxtecan in clinical trials.

The key question will be whether later-stage data can provide stronger evidence of the drug's safety and effectiveness and support a future regulatory submission.

The companies will also continue developing the other programs included in their cancer partnership.

For the pharmaceutical industry, the case highlights the importance of having strong clinical evidence before moving a promising cancer treatment toward commercialization.

What This Means for Healthcare Marketers

The development creates several important signals for healthcare marketers working with pharmaceutical and oncology companies:

  • Regulatory setbacks: A withdrawn application can change launch timelines, commercial planning, and expected market opportunity.
  • Clinical-trial activity: Continued Phase 3 enrollment signals that the company still sees potential in the treatment.
  • Pipeline monitoring: Tracking individual drug programs can reveal where pharmaceutical companies are increasing or reducing commercial investment.
  • Oncology competition: Changes in cancer pipelines can affect future provider education, market-access strategies, and competitive positioning.
  • Partnership signals: Large pharma-biotech partnerships can create long-term opportunities across clinical development, commercialization, analytics, and market access.
  • Regulatory intelligence: FDA decisions and application withdrawals can help marketers understand which products are moving toward or away from commercialization.
  • Launch timing: A regulatory delay can shift when companies need physician engagement, patient support, market research, and commercial infrastructure.

For B2B healthcare marketers, clinical and regulatory milestones are valuable buying signals. A company continuing a Phase 3 program may still be building toward future commercialization even when an earlier regulatory pathway does not succeed.

Key Takeaways

  • Merck and Daiichi Sankyo withdrew their U.S. application for ifinatamab deruxtecan, an experimental lung cancer treatment.
  • The FDA determined that the available mid-stage clinical data did not meet the requirements for accelerated approval.
  • The drug targets B7-H3 and belongs to the antibody-drug conjugate class.
  • It was being studied for patients with extensive-stage small cell lung cancer whose disease had progressed after standard chemotherapy.
  • The companies are continuing Phase 3 studies, so drug development has not ended.
  • The treatment is part of Merck and Daiichi Sankyo's up-to-$22 billion oncology partnership.
  • Another drug from the same partnership, patritumab deruxtecan, previously faced a U.S. application withdrawal.
  • Future clinical data will determine whether ifinatamab deruxtecan can support a new regulatory application.